Quality starting material: The driving force behind life-saving cell therapies

This piece was originally published in November 2019 on CellandGene.com We are living through one of the most exciting eras biopharmaceutical science has ever seen. Following the first U.S. and European regulatory approvals of gene therapies and CAR-T therapies in recent years, activity in this industry has skyrocketed. In the U.S., more than 800 clinical…

Efficiencies gained from the Quality System Audit Program

Three things to know about efficient qualification of collection centers

Ensuring cell collection centers and cell therapy labs are meeting FDA regulatory requirements and providing high-quality starting material for your cell or gene therapy is critical to your therapy’s success. As the industry continues to rapidly advance, it is becoming more critical to integrate process efficiencies wherever possible. There is a solution: using an established…

Amy Hines, director of Collection Network Management, Be The Match BioTherapies

Q&A with Amy Hines, director of Collection Network Management

Amy Hines, BSN, RN, oversees the Be The Match BioTherapies® Collection Network, which includes apheresis centers, marrow collection centers and cell therapy labs. She talked to us about some of the challenges the Network is facing, how Be The Match BioTherapies can help build efficiencies and how the organization plans to save more lives internationally.…